SRI 31215 TFA |
| Catalog No.GC34811 |
Le SRI 31215 (TFA) est un triplex inhibiteur de l'activateur du facteur de croissance de la matriptase/hépsine/hépatocyte (HGFA) et imite l'activité de HAI-1/2 (inhibiteurs endogènes de l'activation de l'HGF). Le SRI 31215 a une puissante activité inhibitrice contre la matriptase, l'hepsine et le HGFA avec des valeurs IC50 de 0,69 μM, 0,65 μM et 0,30 μM, respectivement. Le SRI 31215 peut être utilisé pour la recherche sur le cancer.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1832686-44-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
SRI 31215 (TFA), a triplex inhibitor of matriptase, hepsin and hepatocyte growth factor activator (HGFA) with IC50s of 0.69 μM, 0.65 μM, 0.3 μM, blocks pro-HGF activation and thus mimics the activity of HAI-1/2[1]. IC50: 0.69 μM (matriptase), 0.65 μM (hepsin), 0.3 μM (HGFA)[1]
[1]. Owusu BY, et al. Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling. Oncotarget. 2016 May 17;7(20):29492-506.
Average Rating: 5 (Based on Reviews and 26 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *